Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy: Retinal neovascularization in mice and retinal vascular permeability in diabetic rats

Rosemary J. Santulli, William A. Kinney, Shyamali Ghosh, Bart L. DeCorte, Li Liu, Robert W A Tuman, Zhao Zhou, Norman Huebert, Sven E. Bursell, Alan C. Clermont, Maria B. Grant, Lynn C. Shaw, Shaker A. Mousa, Robert A. Galemmo, Dana L. Johnson, Bruce E. Maryanoff, Bruce P. Damiano

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The αV integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable αV antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,β,S)-1,2,3,4-Tetrahydro-β-[[1- [1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl] -3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide αV antagonist derived from the arginine-glycine- asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits αVβ3 and αVβ5 binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins αIIbβ3 and α5β 1, and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first αV antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)894-901
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume324
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Retinal Neovascularization
Retinal Vessels
Capillary Permeability
Integrins
Animal Models
Macular Degeneration
Vitronectin
Macular Edema
Fibroblast Growth Factors
Diabetic Retinopathy
Cell Movement
Chorioallantoic Membrane
Retinopathy of Prematurity
Asparagine
Glycine
Vascular Endothelial Growth Factor A
Oral Administration
Arginine
Therapeutics
Endothelial Cells

ASJC Scopus subject areas

  • Pharmacology

Cite this

Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy : Retinal neovascularization in mice and retinal vascular permeability in diabetic rats. / Santulli, Rosemary J.; Kinney, William A.; Ghosh, Shyamali; DeCorte, Bart L.; Liu, Li; Tuman, Robert W A; Zhou, Zhao; Huebert, Norman; Bursell, Sven E.; Clermont, Alan C.; Grant, Maria B.; Shaw, Lynn C.; Mousa, Shaker A.; Galemmo, Robert A.; Johnson, Dana L.; Maryanoff, Bruce E.; Damiano, Bruce P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 324, No. 3, 03.2008, p. 894-901.

Research output: Contribution to journalArticle

Santulli, RJ, Kinney, WA, Ghosh, S, DeCorte, BL, Liu, L, Tuman, RWA, Zhou, Z, Huebert, N, Bursell, SE, Clermont, AC, Grant, MB, Shaw, LC, Mousa, SA, Galemmo, RA, Johnson, DL, Maryanoff, BE & Damiano, BP 2008, 'Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy: Retinal neovascularization in mice and retinal vascular permeability in diabetic rats', Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 894-901. https://doi.org/10.1124/jpet.107.131656
Santulli, Rosemary J. ; Kinney, William A. ; Ghosh, Shyamali ; DeCorte, Bart L. ; Liu, Li ; Tuman, Robert W A ; Zhou, Zhao ; Huebert, Norman ; Bursell, Sven E. ; Clermont, Alan C. ; Grant, Maria B. ; Shaw, Lynn C. ; Mousa, Shaker A. ; Galemmo, Robert A. ; Johnson, Dana L. ; Maryanoff, Bruce E. ; Damiano, Bruce P. / Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy : Retinal neovascularization in mice and retinal vascular permeability in diabetic rats. In: Journal of Pharmacology and Experimental Therapeutics. 2008 ; Vol. 324, No. 3. pp. 894-901.
@article{c8a24c14379a486b8f3fd4f26b2f6c79,
title = "Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy: Retinal neovascularization in mice and retinal vascular permeability in diabetic rats",
abstract = "The αV integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable αV antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,β,S)-1,2,3,4-Tetrahydro-β-[[1- [1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl] -3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide αV antagonist derived from the arginine-glycine- asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits αVβ3 and αVβ5 binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins αIIbβ3 and α5β 1, and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first αV antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.",
author = "Santulli, {Rosemary J.} and Kinney, {William A.} and Shyamali Ghosh and DeCorte, {Bart L.} and Li Liu and Tuman, {Robert W A} and Zhao Zhou and Norman Huebert and Bursell, {Sven E.} and Clermont, {Alan C.} and Grant, {Maria B.} and Shaw, {Lynn C.} and Mousa, {Shaker A.} and Galemmo, {Robert A.} and Johnson, {Dana L.} and Maryanoff, {Bruce E.} and Damiano, {Bruce P.}",
year = "2008",
month = "3",
doi = "10.1124/jpet.107.131656",
language = "English (US)",
volume = "324",
pages = "894--901",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Studies with an orally bioavailable αV integrin antagonist in animal models of ocular vasculopathy

T2 - Retinal neovascularization in mice and retinal vascular permeability in diabetic rats

AU - Santulli, Rosemary J.

AU - Kinney, William A.

AU - Ghosh, Shyamali

AU - DeCorte, Bart L.

AU - Liu, Li

AU - Tuman, Robert W A

AU - Zhou, Zhao

AU - Huebert, Norman

AU - Bursell, Sven E.

AU - Clermont, Alan C.

AU - Grant, Maria B.

AU - Shaw, Lynn C.

AU - Mousa, Shaker A.

AU - Galemmo, Robert A.

AU - Johnson, Dana L.

AU - Maryanoff, Bruce E.

AU - Damiano, Bruce P.

PY - 2008/3

Y1 - 2008/3

N2 - The αV integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable αV antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,β,S)-1,2,3,4-Tetrahydro-β-[[1- [1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl] -3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide αV antagonist derived from the arginine-glycine- asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits αVβ3 and αVβ5 binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins αIIbβ3 and α5β 1, and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first αV antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.

AB - The αV integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable αV antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,β,S)-1,2,3,4-Tetrahydro-β-[[1- [1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl] -3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide αV antagonist derived from the arginine-glycine- asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits αVβ3 and αVβ5 binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins αIIbβ3 and α5β 1, and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first αV antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=40849105041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849105041&partnerID=8YFLogxK

U2 - 10.1124/jpet.107.131656

DO - 10.1124/jpet.107.131656

M3 - Article

C2 - 18083913

AN - SCOPUS:40849105041

VL - 324

SP - 894

EP - 901

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -